Because we have NO stroke leadership and NO stroke strategy we get wastes of money and time for research like this.
Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: A multiple-treatments meta-analysis
- The scheme of this research was a multiple-treatments meta-analysis of randomised controlled trials.
- The recruitment comprised of patients with depression, following stroke.
- The intervention constituted 10 antidepressants and placebo in the acute treatment of PSD.
- The primary outcomes were the overall efficacy, defined as the mean change of the total depression score.
- The secondary outcome was the acceptability, defined as risk of all-cause discontinuation.
- These estimates as standardised mean differences or ORs with 95% Cis.
- 12 suitable trials were determined, with data from 707 participants.
- All drugs were markedly more effective than placebo apart from sertraline, nefiracetam and fluoxetine.
- Maximum comparisons for acceptability did not disclose any significant variations.
- The exception was paroxetine having markedly lower all-cause discontinuation than doxepin, citalopram and fluoxetine.
- Difference was noted in the standardised mean differences compared with placebo for efficacy from -6.54 for the best drug (reboxetine) to 0.51 for the worst drug (nefiracetam).
- ORs compared with placebo for acceptability ranged from 0.09 for the best drug (paroxetine) to 3.42 for the worst drug (citalopram).
- For the efficacy rank, reboxetine, paroxetine, doxepin and duloxetine served as the most efficacious treatments, the cumulative probabilities of which were 100%, 85.7%, 83.2%, 62.4%, respectively.
- While taking into account the acceptability rank, paroxetine, placebo, sertraline and nortriptyline were among the most acceptable therapies.
- Their cumulative probabilities were 92.4%, 63.5%, 57.3%, 56.3%.